Disintegrin and metalloprotease proteins (ADAMs) are membraneanchored glycoproteins involved in cell adhesion, cell fusion, protein ecto-domain shedding, and intracellular signaling. We examined whether the disintegrin domain of containing an Asp-Gly-Asp (RGD) integrin-binding motif could interfere with airway smooth muscle cell (ASMC) adhesion and migration. Recombinant ddADAM-15 adhered to human ASMCs with saturation kinetics, and was b 1 -integrin dependent. ddADAM-15 inhibited the binding of fibrinogen but not of fibronectin to ASMCs. ddADAM-15 also inhibited platelet-derived growth factor (PDGF)-induced ASMC migration, and this was reversed by an anti-b 1 -integrin antibody. PDGF induced the activation of phosphoinositol-3-kinase (PI3K) and p38 mitogen-activated protein kinase (MAPK), and selective inhibitors of these kinases inhibited PDGF-induced ASMC migration. ddADAM-15 did not inhibit PDGF-induced activation of PI3K or p38, thereby excluding these kinase pathways as a mechanism by which ddADAM-15 inhibits ASMC migration. ADAM-15 mRNA and protein were expressed under basal conditions, and both gene and protein expression were inhibited by PDGF. In summary, ddADAM-15 inhibits ASMC adhesion and migration through the b 1 -integrin, without modulating signaling pathways involved in ASMC migratory responses.
Disintegrin and metalloprotease proteins (ADAMs) or metalloprotease/disintegrin/cysteine-rich (MDC) proteins are a family of more than 30 membrane-anchored glycoproteins (1) (2) (3) (4) , whose functions include proteolysis, cell adhesion, cell fusion, protein ecto-domain shedding, and intracellular signaling (5) (6) (7) . ADAMs are composed of a pro-domain, a metalloproteinase, a disintegrin domain, and a cysteine-rich region containing an epidermal growth factor (EGF) repeat, a transmembrane domain, and a cytoplasmic tail. The disintegrin domains of ADAMs represent potential binding sites for cell adhesion and signaling receptors of the integrin superfamily. The integrin binding motif is characteristically a tripeptide sequence that is exposed within a loop and, together with the N-and C-terminal flanking regions, determines the specificity and affinity of ADAMs toward distinct integrins (8) (9) (10) . Integrins provide a physical connection between the internal and external cellular environment through their cytoplasmic regions, which interact with cytoskeletal proteins, and constitute an interface in which mechanical forces, cytoskeletal reorganization, and biochemical signals may converge (11) (12) (13) (14) (15) . ADAM-15 is unique in containing the integrin binding motif Arg-Gly-Asp (RGD) within its disintegrin region (16) (17) (18) (19) .
The airway smooth muscle cell (ASMC) through its contractile properties and geometric disposition around the airways contributes to the control of airway caliber. However, the ASMC is more than a contractile cell, since it can synthesize inflammatory cytokines and chemokines and has a proliferative capacity (20, 21) . ASMCs are remodeled in disease states such as asthma, where they are in an increased proliferative state (22) and are increased in size and in number (23, 24) . ASMCs interact with extracellular matrix (ECM) proteins such as collagen through integrin attachment, and attachment through the a 5 b 1 -integrin promotes ASMC survival (25) . It has been proposed that increased airway smooth muscle mass may be the result of migration of ASMC precursors such as myofibroblasts into the muscle bundle (26) . Migration of the ASMC is dependent on its interaction with the surrounding matrix.
The role of ADAMs in ASMC biology is not known. We chose to study ADAM-15 and hypothesized that ADAM-15, through its disintegrin properties, may interfere with ASMC adhesion and migration. We synthesized the disintegrin domain of ADAM-15 (ddADAM-15), and to examine the specific role of the unique RGD peptide sequence contained within the disintegrin domain, we synthesized ddADAM-15 mutants that contained integrin-binding motifs of other ADAM proteins. We then determined the effect of ddADAM-15 and ddADAM-15 mutants on ASMC adhesion to fibrinogen and fibronectin, and on platelet-derived growth factor (PDGF)-induced ASMC migration. We also determined whether ADAM-15 is expressed in ASMC.
MATERIALS AND METHODS

Preparation of ddADAM-15 and Mutants
A cDNA fragment that encodes the disintegrin-like domain of ADAM-15 (Met 420 to Glu 510 ) was amplified by PCR with pcDNA3 as a template. The PCR fragment was digested by EcoR1and BamH1, then cloned into the restricted vector pGEX-3X (Amersham Biosciences, Piscataway, NJ) at the carboxyl terminus of the glutathione Stransferase (GST) gene and transformed in DH5a Escherichia coli strain. For the generation of ddADAM15 containing a disintegrin loop derived from ADAM-2, -12, -19, -28, a two-run PCR method was developed. The first-run PCR generated the sequence encoding the individual loop and the second-run downstream elongates the sequence encoding the C-terminal residues. The products were ethanol-precipitated to reduce the volume for the digestion with BamHI and EcoRI,
CLINICAL RELEVANCE
The disintegrin domain of ADAM-15 is shown to be capable of controlling the migration of smooth muscle cells by modulating intracellular signaling. This property is likely to engender specific roles for each ADAMs protein in healthy or diseased airways. then gene-cleaned again before ligation. After ligation, the construct was transformed in the same DH5a E. coli strain.
Protein Expression and Purification
ddADAM-15 was expressed in E. coli. The culture was inoculated with an overnight seed culture (1%, vol/vol) in 23 YT/ampicillin medium (100 mg/ml). Isopropyl b-D-thiogalactoside (0.1 mM) was added for induction. GST-ddADAM-15 was purified from the supernatant of sonicated cells by affinity chromatography, using glutathione-sepharose 4B columns in the presence of trypsin inhibitor (50 mg/ml), pepstatin (10 mg/ml), aprotinin (10 ml stock), EDTA (0.5 M) and phenylmethanesulfonyl fluoride (100 mM in ethanol). The recombinant ddADAMs were released from GST-fusion proteins by digestion with factor Xa (1:300, wt/wt, factor Xa: fusion protein) at 48C for 12 hours. The product was purified by reverse-phase HPLC (Waters 515) with a Vydac C 18 analytical column.
ASMC Cultures
Human bronchial tissue was obtained from the lungs of patients undergoing surgical resection for carcinoma. All patients gave informed consent as to the use of the lung tissue and the project was approved by the Ethics Committees of St. Mary's and Royal Brompton Hospitals. ASMCs were dissected out and prepared using established methods (27) . Briefly, bands of smooth muscle from bronchi were cut out from surrounding connective tissue and resuspended in 1 ml Dulbecco's modified Eagle's medium (DMEM) containing 1 mg/ml collagenase and kept in a humidified atmosphere of 5% CO 2 for 30 to 60 minutes. The resulting cell suspension was centrifuged under 200 3 g for 5 minutes, and pellets from the centrifugation were resuspended in DMEM media supplemented with 10% fetal calf serum. The cells were grown to confluence, passaged, and transferred to T175 tissue culture flasks. ASMC characteristics were identified by light microscopy with the ''hill and valley'' appearance and by positive immunostaining of smooth muscle (SM) a-actin, SM myosin heavy chain, SM-22, and calponin.
RNA Extraction and Real-Time PCR
Confluent ASMCs in 6-well plates were serum-deprived in DMEM containing 0.5% bovine serum albumin (BSA) for 24 hours. Cells were then treated with PDGF for a further 24 hours. Total cellular RNA was extracted from ASMCs using the Qiagen RNeasy mini Kit (Qiagen, Crawley, UK) according to the manufacturer's instructions. Singlestranded complementary DNA (cDNA) was synthesized from 0.5 mg of RNA by RT-PCR using AMV reverse transcriptase and random hexamers. Real-time PCR was performed by monitoring PCR product accumulation in real-time during the entire PCR cycling by fluorescence detection of SYBR Green dye (Rotor Gene 3000; Corbett Life Science, Sydney, Australia). The primer sequence pairs used were derived from the target cDNA sequence: ADAM-15 sense: 59-CCGACGGGCCCTGGAGAAAG-39 and antisense: 59-GCTGGGC ATAGGAGGCACAAC-39. Cycling conditions were as follows: Step1, 15 minutes at 948C; Step2, 20 seconds at 948C; Step3, 20 seconds at 678C; and Step4, 20 seconds at 728C. Steps 2 to 4 were repeated for 50 cycles. Data acquired were analyzed using the software supplied from the manufacture. Relative quantification of gene expression was calculated with GAPDH as control.
Western Blot Analysis for ADAM-15
ASM cells were lysed on ice to extract cell protein using lysis buffer (1% Igepal CA-630, 0.5% sodium deoxycholate, 0.1% SDS in PBS, pH 7.4) along with the following inhibitors: 1 mM PMSF, 5mg/ml aprotinin, 1 mM Na 3 VO 4 , and 5mg/ml leupeptin. Protein extract (15 mg per lane) was electrophoresed on 4-12% Criterion XT gels (Bio-Rad, Herts, UK) and then transferred to a blot membrane using an LKB semi-dry transfer unit (LKB, Stockholm, Sweden). ADAM-15 was then detected using purified polyclonal antibody (28) (kindly provided by John Martin, University of Wales College of Medicine, Cardiff, Wales, UK) raised against the disintegrin domain of ADAM-15. The antibody was immunoreactive against the specific disintegrin domain but not against the cytoplasmic or metalloproteinase domains of ADAM-15. The specific band was visualized using the enhanced chemiluminescence detection reagents and analysis system (Amersham Biosciences).
ASMC Adhesion Assay
96-well plates were coated overnight by incubation with solutions of fibronectin, fibrinogen, or ddADAM-15. Harvested ASMCs were resuspended in Tyrode's wash buffer. Cells were spun at 1,000 3 g for 5 minutes and resuspended in Tyrode's wash buffer. Cells were then spun and resuspended in Tyrode's buffer containing 2 mM of MnCl 2 . The cells were then treated with or without anti-integrin antibodies (5 mg/ml) or with the appropriate isotype control for 30 minutes before adding to microtiter wells (100 ml of 1 3 10 6 cells) coated with ddADAM-15 acting as a ligand. The plates were incubated for 1 hour at 258C and wells were washed with Tyrode's wash buffer. The number of adherent cells was determined by measurement of endogenous acid phosphatase at an absorbance of 450/650 nm. 
ASMC Migration Assay
Migration assays were performed using Transwell 8-mm permeable membranes (Fisher Scientific, Loughborough, UK) coated with a 1% collagen solution (Cohesion, Eindhoven, The Netherlands). Confluent ASMCs were serum-deprived in DMEM containing 0.5% BSA for 24 hours before being used in migration assays. Cells were resuspended at a density of 1 3 10 6 cells/ml, and 100 ml of cell suspension was used. PDGF and/or ddADAM-15 were added to the lower chamber and cells were allowed to migrate over a 16-hour period. Cells on the upper face of the membrane were removed and migrated cells on the lower face were fixed in 100% methanol and stained with Diff-Quik solution (Dade Behring, Eschborn, Germany). Cells were counted under 340 magnification in five random fields.
Flow Cytometric Analysis of ASMC Surface Integrins
ASMCs were serum-deprived in DMEM containing 0.5% BSA for 24 hours before treatment with PDGF (0.8 nM) for a further 16 hours. This stimulation period was chosen as it was used in the cell migration assays. Cells were trypsinized, washed in 1% PBS, and incubated with the primary monoclonal anti-integrin antibodies (Chemicon, Hampshire, UK) or the appropriate isotype control (Beckman Coulter, Buckinghamshire, UK) (2 mg/10 5 cells, 30 min). After a wash with PBS, cells were incubated with the fluorescein isothiocyanate (FITC)-tagged secondary antibody (2 mg/10 5 cells, 30 min; Beckman Coulter). Further washes were performed with PBS and cells were then resuspended in binding buffer. Flow cytometric analysis was performed using a Beckmann Coulter FC 500 flow cytometer.
Measurement of p38 MAPK and PI3 Kinase Phosphorylation
Measurement of phosphorylated p38 and PI3K and total p38 and PI3K protein was performed using Fast Activated Cell Based ELISA (FACE) assays (Active Motif, Rixensart, Belgium) according to the manufacturers' instructions. ASMCs were grown to 90% confluence in 96-well plates and placed in fresh serum-free supplemented DMEM for 24 hours before treatment.
Data Analysis
Data are presented as mean 6 SEM. Comparison between groups were performed using one-way ANOVA followed by the Newman-Keuls post test to determine statistical significance. A P value of , 0.05 was taken as statistically significant. were initially tested for their ability to bind ASMCs. ddADAM-15 bound to ASMCs in a dose-dependent and saturable manner, with maximal effect at 2.8 mM. The binding ability of ddADAM-15 was weaker when compared with the glycoproteins fibrinogen (2.8 mM) and fibronectin (2.8 mM), but stronger when compared with ddADAM-15 containing any other disintegrin-like loop ( Figure 1A) . We then determined whether ddADAM-15 competes with fibrinogen or fibronectin for adherence to ASMC. ddADAM-15 inhibited fibrinogen binding to ASMCs in a dose-dependent manner. A maximal effect of 90% was observed at 1.5 mM ddADAM-15, a 5-fold higher concentration than that causing maximal adherence. ddADAM-15 did not inhibit fibronectin attachment to ASMCs. Thus, ddADAM-15 may have overlapping integrin-binding sequences to fibrinogen, but not to fibronectin ( Figure 1B) .
RESULTS
Binding of ddADAMs to ASMCs
To establish which integrin(s) were mediating ASMC adherence to ddADAM-15, blocking anti-human monoclonal antibodies (mAbs) against the a 4 , a 5 , a 6 , a V , b 1 , and b 3 subunits and the a 2 b 1 and a IIb b 3 complexes were used (10 mg/ml each). The anti-b 1 antibody caused z 80% inhibition of ddADAM-15 binding to ASMCs. The other mAbs used had no significant effect, indicating that this adhesion was predominantly b 1 dependent ( Figure 1C ). The appropriate isotype control did not cause any significant effect.
ddADAM-15 Inhibits PDGF-Induced ASMC Migration
We investigated whether ddADAM-15 modulates ASMC migration induced by PDGF-BB. ddADAM-15 alone had no effect on baseline ASMC migration (data not shown). PDGF stimulated ASMC migration and displayed a classical chemokine bell-shaped dose response curve, with maximal migratory activity observed at 2.2 nM (Figure 2A) . Submaximal concentration of PDGF (0.8 nM) was used in subsequent experiments. ddADAM-15 inhibited PDGF induced ASMC migration in a dose-dependent manner, causing maximal inhibition of z 70% at 4 mM ( Figure 2B) . A single amino-acid substitution of arginine (R 64 ) to alanine (A 64 ) in the RGD tri-peptide disintegrin domain abolished the inhibitory effect of ddADAM-15, indicating an absolute requirement of the RGD-tripeptide for this inhibitory activity ( Figure 2C ). An anti-b 1 antibody completely inhibited PDGF-induced ASMC migration, whereas an anti-a V antibody had a partial effect, with z 50% inhibition. Antibodies directed against a 5 or b 3 integrins had no effect on PDGFinduced migration ( Figure 2D) . Flow-cytometric analysis of b 1 , b 3 , a v , and a 5 expression on ASMC revealed predominant expression of the b 1 -integrin. PDGF (0.8 nM) had no effect on the expression of these integrins (Figure 3 ).
PI3Kinase and MAP Kinases in ASMC Migration and Effect of dd-ADAM15
We used chemical inhibitors to determine the role of PI3 kinase, as well as the p38, extracellular signal-regulated kinase (ERK), and c-jun N-terminal (JNK) MAP kinases in PDGF-induced ASMC migration. The PI3 kinase inhibitor LY294002 (10 mM) and the p38 inhibitor SB203580 (5 mM) almost completely inhibted PDGF-induced migration, whereas inhibition of ERK with PD98029 (10 mM) or JNK with SP600125 (10 mM) had no effect (data not shown). Treatment with these inhibitors alone had no effect on ASMC migration (data not shown). Consistent with these findings, we demonstrated phosphorylation of both p38 and PI3 kinase 10 and 15 minutes, respectively, after stimulation with PDGF (0.8 nM) (data not shown). Interestingly, however, ddADAM-15 did not inhibit PDGF-induced phosphorylation of PI3 kinase or p38, nor did it further inhibit PI3 kinase or p38 phosphorylation activity in the presence of their respective inhibitors, indicating that ddADAM-15 did not interfere with these signaling activation pathways (Figure 4 ).
Endogenous Expression of ADAM-15 in ASMC
We determined whether there was endogenous expression of ADAM-15 in unstimulated ASMC, and whether endogenously expressed ADAM-15 inhibited PDGF-induced ASMC migration. Using quantitative real-time PCR, ADAM-15 mRNA was detected under basal conditions. PDGF caused a dose-dependent inhibition of endogenous ADAM-15 mRNA, particularly at concentrations of 0.8 and 1.6 nM ( Figure 5A ). PDGF (1.6 nM) caused a time-dependent inhibition of ADAM-15 expression, maximal after 24 hours ( Figure 5B ). We also determined that TGF-b (10 ng/ml), IL-1b (10 ng/ml), IL-4 (10 ng/ml), and EGF (40 ng/ml) also inhibited ADAM-15 gene expression to an extent similar to that of PDGF ( Figure 5C ). Using Western blotting, we detected the presence of a 110-kD protein band, 
DISCUSSION
We have shown that ddADAM-15 can bind to ASMCs and that this binding can be modulated by different putative disintegrin-like loops within the ddADAM-15 scaffold. This adhesion was predominantly mediated by the b 1 -integrin. Hence, ddADAM-15 can serve as preferential b 1 -integrin antagonist as shown by inhibition of ASMC adhesion toward immobilized fibrinogen. Furthermore, ddADAM-15 inhibited PDGF-induced cell migration, with the RGD-motif of ddADAM-15 playing a crucial role. Finally, although ASMC migration was blocked by selective kinase inhibitors of PI3K and p38 MAPK, the inhibitory role of ddADAM-15 in that respect was not accompanied by inhibition of these kinases.
The adhesive-promoting activity of ddADAM-15 is specifically due to the integrin-binding RGD sequence located in a putative disintegrin-like loop of ddADAM-15, as the replacement of the putative disintegrin-like loop with those of ADAM-2, -12, and -19 showed a dramatic decrease in binding ability. Although both fibrinogen and fibronectin can use b 1 -integrin binding to ASMC, only fibrinogen but not fibronectin binding was blocked by ddADAM-15 in a dose-dependent manner. This preferential antagonism implied that ddADAM-15 and fibrinogen may share the same or a closely related region of the b 1 -integrin-binding site; such a region may not be involved in fibronectin binding despite the location of an RGD sequence in the 10th type III repeat of fibronectin, which is the major binding site for b 1 -integrin, for example as with a 5 b 1 (29, 30) . The role of RGD in ddADAM-15 may be limited, as this is the only ADAM family protein containing this sequence. It cannot be ruled out that other regions beyond the disintegrin-like loop may also play a role in integrin-binding ability, since ddADAM-15, as well as ddADAM-12 (which lacks the RGD-motif), can interact with b 1 -associated a 9 integrin (31), and a 5 integrin (19) , in other cell types. 
